San Francisco, November 1, 2022 – Recardio Inc. today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the companies entering the global pivotal Phase 3 trial.
This newly formed Steering Committee represents a selection of world class key opinion leaders and clinicians, who either already contributed to the past clinical development or are now supporting Recardio in the pivotal Phase 3 trial and the scientific and clinical development of its regenerative therapy for acute myocardial infarction.
The Chairman of the Steering Committee is Andrew Coats, President of the Heart Failure Association, University of Warwick and Monash, United Kingdom/Australia.
Further Steering Committee members include:
Deepak Bhatt, PhD, MD, Executive Director of Interventional Cardiovascular Programs, Professor of Medicine, Harvard Medical School, Boston, USA
Tim Friede, PhD, Department of Medical Statistics, University Medical Center, Göttingen, Germany
Carolyn Lam, PhD, MD, Director of Women’s Heart Health of the National Heart Centre Singapore Professor of Duke-NUS Cardiovascular Academic Clinical Program, Singapore
Dirk von Lewinski, PhD, MD, Medical University of Graz, Clinical Department of Cardiology, Graz, Austria
Richard Schatz, PhD, MD, Interventional Cardiology, Research Director Scripps Clinic, Director of Gene and Stem Cell Research, Professor of Medicine, La Jolla, USA
John Teerlink, MD, Professor of Medicine, University of California, San Francisco (UCSF)
Director, Heart Failure Program, VA Medical Center, San Francisco, USA
Stephan Windecker, PhD, MD, Chairman and Professor, Department of Cardiology, Bern University Hospital, Bern, Switzerland
Andrew Coats, Chairman of the Steeering Committee commented: “It is a pleasure working with such a great team evaluating what looks like a really exciting prospect in the mamagement of large STEMIs and the adverse effects of LV remodeling.”
Dr. Roman Schenk, RECARDIO Chairman of the Board commented: “We are extremely proud that key opinion leaders from all around the globe have joined our Steering Committee and will contribute with their excellent and long lasting scientific and clinical experience to our pivotal development program in the cardiovascular area.”
Recardio Inc. is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor having demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardiac tissue after an injury.
Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in preclinical stage.